← board
LYRA
Lyra Therapeuticsdistress 6/10 · elevated risk$0.520%today-94% from 52w high
Lead: chronic rhinosinusitis
Revenue
pre-revenue
Liquidity
$16M
Runway
0.6 yrs
Shares 1y
+8%
Price & events
-76.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
-0.5%
1W
-8.8%
1M
-31.7%
3M
-76.4%
6M
-93.7%
1Y
-96.4%
2Y
-99.9%
5Y
-99.9%
All
Overview
- Market Cap
- $922.94K
- Volume
- 0
- 52 Week Range
- $0.37 – $8.71
- Total Shares
- 1.77M
- Float Shares
- 336.13K
- Short %
- 1.10%
- % Held by Insiders
- 0.62%
- % Held by Institutions
- 12.53%
- Beta
- 0.69
Pipeline stages · 1 programs
LYR-210, Sham procedure control
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-04-02 | Phase 3 | LYR-210, Sham procedure control | Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis) | 182 | completed |
Catalyst news & presentations · 5
- 1H 2026trial initiationsecondaryPhase 3LYR-210 · Phase 3 trial planned to initiate in first half of 2026SEC 8-K
- 2026-01-09trial discontinuedLYR-210 · Suspended further development of LYR-210 for chronic rhinosinusitisSEC 8-K
- Q2 2025readoutPhase 3LYR-210 · Topline data from ENLIGHTEN 2 Phase 3 trialSEC 8-K
- second half of 2024enrollment completesecondaryPhase 3LYR-210 · ENLIGHTEN 2 enrollment completion expectedSEC 8-K
- Q4 2024readoutPhase 3LYR-210 · ENLIGHTEN 1 52-week extension study topline resultsSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-08-14HC Wainwright & Co.Neutral
- 2025-06-10HC Wainwright & Co.Neutral
- 2025-03-14HC Wainwright & Co.Neutral
- 2024-08-15Cantor FitzgeraldOverweight
- 2024-08-15HC Wainwright & Co.Neutral
Competitors — chronic rhinosinusitis
Recent news
- 2026-07-09Lyra Therapeutics stock trades steadily as sinusitis implant program advances - Ad-hoc-news.de
- 2026-07-07Enterprise value to revenue forward of Lyra Therapeutics, Inc. – OTC:LYRA - TradingView
- 2026-04-17Lyra Therapeutics, Inc. Announces Intention to Voluntarily - GlobeNewswire
- 2026-04-17Lyra Therapeutics to delist from Nasdaq, suspend SEC reporting - Investing.com
- 2026-04-17Lyra Therapeutics ends Waltham sublease, agrees to $2.1 million termination payment - Investing.com
- 2026-04-13After layoffs, Lyra Therapeutics exits Watertown and Waltham leases - The Business Journals
- 2026-04-10Lyra Therapeutics to end leases early for Watertown and Waltham facilities - Investing.com
- 2026-03-16LYRA THERAPEUTICS INC (LYRA) Stock Chart - ChartMill
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.